Four regions across the Taiwan Straits signed an agreement on Biomedical Innovation and cooperation

Source: China pharmaceutical innovation promotion association October 30, 2017 On October 29, 2017, at the opening ceremony of the second China Pharmaceutical Innovation and investment conference, song Ruilin, executive chairman of China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association"), Qian Zongliang, executive chairman of Taiwan biotechnology and Medical Industry Promotion Association (hereinafter referred to as "health Policy Association"), Lu Yulin, chairman of Hong Kong Biomedical Innovation Association, and Wang Yitao, President of Macao International Chinese Medicine Quality Research Association made The agreement on Biomedical Innovation and cooperation between the two sides and four regions was signed for the representatives of the four associations It was announced that the four associations would give full play to the platform advantages of non-governmental associations, and work together to expand exchanges and cooperation in scientific research, clinical, industrial and policy fields, so as to provide a platform and link for innovation and cooperation for the Chinese forces in the four regions of the two sides and even in the global biomedical industry, and jointly promote the innovation and cooperation of China's biomedical industry New development and prosperity Sifang will jointly prepare to establish the China biomedical innovation and cooperation committee, and set up a number of special committees including R & D, clinical, investment, supervision, etc to invite and convene leaders from four regions and overseas Chinese biomedical field to join in, and carry out multi field cooperation and sharing based on this, promote scientific research cooperation and multi center clinical trials and data interaction, and improve the cooperation and cooperation of the regulatory system In the same way, we should open up and expand financing channels in the region and at home and abroad, provide more financial support for pharmaceutical innovation in the four regions, strive to achieve the synchronous registration and listing of innovative drugs in the region, promote the market circulation of innovative drugs in the region, so as to meet public health needs faster and improve the drug access of patients Group photo of signing leaders: (from the left) Lu Yulin, Song Ruilin, Qian Zongliang and Wang Yitao from both sides of the Taiwan Strait and Hongkong and Macao, with the largest population in the world and the second largest pharmaceutical market in the world Since 2008, under the promotion of national policies, mainland China has become a new highland of biomedical innovation After decades of development and accumulation, Hong Kong, Macao and Taiwan have strong biomedical innovation strength and industrial capacity At present, with mainland China as the core, covering Taiwan, Hong Kong and Macao, it has become one of the most competitive regions in the world in the fields of biomedical basic research, new drug research and development In this context, the four associations signed a cooperation agreement based on the common goal and fully strengthened the sharing and co construction in the fields of new drug research and development, clinical trials, industrial development, policy supervision, etc., which is not only conducive to giving full play to their respective advantages and working together to solve the practical problems of public health in the region, but also conducive to improving the overall level and industrial capacity of China's pharmaceutical innovation and enhancing China's biomedical industry The competitiveness of drugs in Asia and even in the world Innovation is the common pursuit of the pharmaceutical industry in the four regions across the Straits, and cooperation and development are the consensus of all parties Facing the common challenges and innovative drug demand in the field of public health, it is in line with the common interests of the people in the region to strengthen pharmaceutical innovation cooperation, promote the coordinated governance of public health and the transformation and upgrading of pharmaceutical industry Through the strong cooperation of professional groups in the four regions, we will further enhance mutual trust and public exchanges in the industry, promote close cooperation between the pharmaceutical industry in the four regions on both sides of the Taiwan Strait, and contribute to strengthening national consensus and national cohesion, which is of great significance Attachment: brief introduction of four associations China Pharmaceutical Innovation and Research Development Association, Phirda) is a state-level social organization approved by the Chinese government in 1988 It is composed of the most influential drug research and development institutions, scientific research institutes and clinical trial institutions, pharmaceutical enterprises and investment institutions in China In November 2016, CFDA officially joined the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), which is the only association member representing China's local pharmaceutical industry Over the years, adhering to the tenet of "innovation, industrialization and internationalization", with the goal of promoting the innovative development and improving the innovation ability of Chinese medicine, CFDA has established close and good relations with government departments, R & D circles, industry circles, academia and investment circles, and has promoted the reform of drug review and approval system and medical insurance reimbursement system in China and the implementation of major national new drug projects Construction and other aspects played an important role; became an important bridge between the pharmaceutical industry and the communication between the industry and the government, and made a positive contribution to improving the policy environment of China's pharmaceutical innovation, promoting the development of pharmaceutical innovation and international competitiveness, and further improving the drug accessibility and accessibility of citizens The Institute for biotechnology and medicine industry (ibmi) was founded in March 2002 It is a non-profit social group that integrates government and private resources to promote the integration of biotechnology and medicine industry in Taiwan Over the years, the health policy committee has integrated the strength of production, government, education, research and legislative bodies, assisted the Taiwan authorities to optimize and improve the mechanism in the aspects of biomedical industry policy, market mechanism, innovation environment, etc., and deeply participated in the drafting and formulation of important regional laws such as the regulations on the development of new biomedical industry, the basic law of science and technology, and the medical law, so as to promote the development of Taiwan The development of biotechnology, health care, social welfare and health service industries in the bay area has played a role Since 2008, the health policy committee has gradually strengthened the medical exchange and cooperation with the mainland of China in the mode of folk platform first From 2009 to 2010, the health policy committee participated in and promoted the consultation and signing of the cross strait medical and health cooperation agreement between the mainland and Taiwan health authorities The contents of the agreement not only cover the medical needs of disease control, acute and severe diseases, but also clearly carry out bilateral new drug research and development and clinical trial cooperation based on the international ICH standards, laying a foundation for accelerating the cooperation of biotechnology industry between the two places and improving the competitiveness of the international market Hong Kong Biomedical Innovation Association is committed to giving full play to Hong Kong as an international city, giving full play to the advantages of academic institutions and research institutions in line with international standards, and promoting the development of biomedical industry Macao International Association of quality research in Chinese medicine (iaqrcm) is a professional organization approved by the government of Macao Special Administrative Region in 2012 to promote the international development of Chinese medicine With the vision of establishing a leading research and cooperation platform for biomedical R & D and biomedical industry development strategy, Sinopharm is funded by Macao Foundation, aiming to unite biomedical professionals at home and abroad to promote the international development of Chinese medicine and the innovation and development of Chinese biomedical industry.